Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) CEO Kevin T. Conroy sold 8,271 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $59.32, for a total transaction of $490,635.72. Following the sale, the chief executive officer now owns 1,299,496 shares of the company’s stock, valued at approximately $77,086,102.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Exact Sciences Stock Performance
Shares of EXAS opened at $58.50 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32. The stock has a market capitalization of $10.62 billion, a P/E ratio of -51.32 and a beta of 1.22. The company’s fifty day moving average is $65.08 and its two-hundred day moving average is $67.78. Exact Sciences Co. has a 1 year low of $56.05 and a 1 year high of $100.77.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. The company had revenue of $646.89 million for the quarter, compared to analysts’ expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. Exact Sciences’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.72) EPS. On average, sell-side analysts predict that Exact Sciences Co. will post -0.86 earnings per share for the current year.
Hedge Funds Weigh In On Exact Sciences
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Guggenheim assumed coverage on shares of Exact Sciences in a research report on Thursday, December 14th. They set a “buy” rating and a $90.00 price objective for the company. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a research report on Tuesday, January 2nd. Wolfe Research started coverage on shares of Exact Sciences in a research report on Wednesday, December 13th. They set an “outperform” rating and a $95.00 price objective for the company. Finally, TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.31.
Check Out Our Latest Stock Report on Exact Sciences
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
- Five stocks we like better than Exact Sciences
- The “How” and “Why” of Investing in 5G Stocks
- Boeing Wants to Buy Its Supplier on Recent Drama, Here’s Why
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Cava Group Serves Up 60% Gain Amid Strong Post-IPO Buying
- Most Volatile Stocks, What Investors Need to Know
- Gitlab Goes on Sale: The AI Bubble Burst for This Stock
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.